Genetically Modified Stem Cells For The Treatment Of Insulin Deficiency In Diabetes

Abstract

Core Objective: The strategy aims to transition from the lifelong, symptomatic management of diabetes
(via external insulin injections) to a functional biological cure by replacing destroyed or exhausted
pancreatic beta cells. Stem Cell Source: Scientists utilize embryonic stem cells or induced pluripotent stem
cells (iPSCs), directing them in a laboratory setting to differentiate into functional, glucose-responsive,
insulin-secreting cells. Genetic Engineering Solutions: Advanced gene-editing tools (such as CRISPR)
are applied to the stem cells prior to transplantation to address key medical barriers: Immune Evasion:
Modifying cells to hide from or resist the host's immune system, eliminating the need for toxic, lifelong
systemic immunosuppressants. Enhanced Viability: Engineering cells to promote rapid blood vessel
growth and survive the hypoxic stress immediately following transplantation. Remaining Obstacles: Key
challenges include managing the theoretical risk of tumor formation from undifferentiated cells,
overcoming high manufacturing and scalability costs, and confirming long-term safety through rigorous
clinical trials.